item management s discussion and analysis of financial condition and results of operations liquidity and capital resources cash provided by operating activities has been and is expected to continue to be the company s primary source of funds 
in  operations provided million of cash compared with million in the company had cash  cash equivalents  and marketable securities of  million at december   compared with million at december  capital expenditures totaled million in compared with million in over the next few years  the company expects to spend approximately million to million per year on capital projects and equipment to expand the company s global operations 
the company receives cash from the exercise of employee stock options 
in  stock options and their related tax benefits provided million of cash compared with million in proceeds from the exercise of stock options and their related tax benefits will vary from period to period based upon  among other factors  fluctuations in the market value of the company s stock relative to the exercise price of such options 
in  the exercise of warrants associated with amgen clinical partners  lp provided million of cash 
the right to exercise these warrants expired on june  the company has a stock repurchase program see note to the consolidated financial statements to offset the dilutive effect of its employee benefit stock option and stock purchase plans 
during the year ended december   the company purchased million shares of common stock at a cost of million compared with million shares purchased at a cost of million in the company expects to repurchase million to million under the program in to provide for financial flexibility and increased liquidity  the company has established several sources of debt financing 
the company has a shelf registration under which it can issue up to million of medium term notes 
at december   million of medium term notes were outstanding which mature in approximately two to eight years 
the company also has a commercial paper program which provides for short term borrowings up to an aggregate face amount of million 
at december   million of commercial paper was outstanding  with maturities of less than three months 
the company also has a million revolving line of credit  which primarily supports the company s commercial paper program 
no borrowings on this line of credit were outstanding at december  the company invests its cash in accordance with a policy that seeks to maximize returns while ensuring both liquidity and minimal risk of principal loss 
the policy limits investments to certain page types of instruments issued by institutions with investment grade credit ratings  and places restrictions on maturities and concentration by type and issuer 
the majority of the company s portfolio is composed of fixed income investments which are subject to the risk of market interest rate fluctuations  and all of the company s investments are subject to risks associated with the ability of the issuers to perform their obligations under the instruments 
the company has a program to manage certain portions of its exposure to fluctuations in foreign currency exchange rates 
these exposures primarily result from european sales 
the company generally hedges the related receivables with foreign currency forward contracts  which typically mature within six months 
the company uses foreign currency option and forward contracts which generally expire within months to hedge certain anticipated future sales 
at december   outstanding foreign currency option and forward contracts totaled million and million  respectively 
the company believes that existing funds  cash generated from operations  and existing sources of debt financing are adequate to satisfy its working capital and capital expenditure requirements and to support its stock repurchase program for the foreseeable future 
however  the company may raise additional capital from time to time to take advantage of favorable conditions in the markets or in connection with the company s corporate development activities 
results of operations product sales in product sales increased million or over the prior year 
in  product sales increased million or over the prior year 
neupogen r filgrastim the company s worldwide neupogen r sales were million in  an increase of million or over the prior year 
in  sales were million  an increase of million or over the prior year 
domestic sales of neupogen r were million in  an increase of million or over the prior year due primarily to increased usage of neupogen r and price increases 
in  domestic sales were million  an increase of million or over the prior year due primarily to the increased usage of neupogen r 
these results reflect the ongoing and intensifying cost containment pressures in the health care marketplace  including use of guidelines in patient care 
this pressure has contributed to the slowing of growth in domestic neupogen r usage over the past several years and is expected to continue to influence such growth for the foreseeable future 
during  neupogen r was approved in the united states to support peripheral blood progenitor cell transplants  the product s fourth indication 
page international sales of neupogen r  primarily in europe  were million in  an increase of million or over the prior year 
three factors  each contributing approximately one third  account for this increase strong unit demand growth  the inclusion of sales from three additional countries as the result of austria  sweden  and finland joining the european union eu on january  and the favorable effects of strengthened foreign currencies 
prior to the entry of the three additional countries into the eu  f 
hoffmann la roche paid the company royalties on sales in these countries under a license agreement 
in  international sales were million  an increase of million or over the prior year 
this increase was primarily due to increased demand 
the company s overall share of the colony stimulating factor market in the eu has decreased since the introduction in of competing colony stimulating factor products 
quarterly neupogen r sales volume in the united states is influenced by a number of factors including underlying demand  seasonal changes in cancer chemotherapy administration  and wholesaler inventory management practices 
wholesaler inventory reductions tend to reduce domestic neupogen r sales in the first quarter each year 
in prior years  neupogen r sales in the eu have experienced a seasonal decline to varying degrees in the third quarter 
epogen r epoetin alfa epogen r sales were million in  an increase of million or over the prior year 
in  epogen r sales were million  an increase of million or over the prior year 
these increases were primarily due to an increase in the us dialysis patient population  the administration of higher doses  and to a lesser extent  increased penetration of the dialysis market 
cost of sales cost of sales as a percentage of product sales was  and for the years ended december   and  respectively 
in  cost of sales as a percentage of product sales is expected to range from to 
research and development in and  research and development expenses increased million or and million or  respectively  compared with the prior years primarily due to expansion of the company s internal research and development staff and increases in external research collaborations 
the current year amount includes a charge for a million signing payment to the rockefeller university and a million charge related to a license fee to nps pharmaceuticals for exclusive licenses to certain technologies 
annual research and development expenses are expected to increase at a rate exceeding the anticipated annual product sales growth rate due to planned increases in internal efforts on new product discovery and page development and increases in external research collaboration costs  including acquisitions of product and technology rights 
write off of in process technology purchased in december  the company acquired synergen  a biotechnology company engaged in the discovery and development of protein based pharmaceuticals 
synergen was acquired for million in cash  including related acquisition costs 
the purchase price was assigned to the acquired tangible and intangible assets based on their estimated fair values at the date of acquisition 
the value assigned to in process technology of million was expensed during the quarter ended december  marketing and selling in and  marketing and selling expenses increased million or and million or  respectively  compared with the prior years 
these increases primarily reflect marketing efforts to increase the number of patients receiving neupogen r and to bring more patients receiving epogen r within the target hematocrit range 
in  marketing and selling expenses combined with general and administrative expenses are expected to have an aggregate annual growth rate lower than the anticipated annual growth in product sales 
general and administrative in and  general and administrative expenses increased million or and million or  respectively  compared with the prior years 
these increases are primarily due to staff related expenses 
in  general and administrative expenses combined with marketing and selling expenses are expected to have an aggregate annual growth rate lower than the anticipated annual growth in product sales 
interest and other income interest and other income increased million or in compared with the prior year 
this increase is primarily due to capital gains realized in the company s investment portfolio during while capital losses were incurred in  higher interest rates earned by the company s investment portfolio during and higher current year cash balances 
interest and other income decreased million or in compared with the prior year 
due to significant increases in interest rates during  the company elected to reposition its fixed income investment portfolio which resulted in capital losses of million for the year 
in  there were no significant capital gains or losses in the investment portfolio 
interest and other income is expected to fluctuate from period to period primarily due to changes in interest rates and cash balances 
page income taxes in  the company s effective tax rate was 
this tax rate reflects tax benefits from the sale of products manufactured in the puerto rico fill and finish facility which began in the first quarter of in  the company s effective tax rate was  which is higher than the company s statutory rate 
this is primarily due to the write off of in process technology purchased in connection with the synergen acquisition  which is not deductible for income tax purposes 
in  the company s effective tax rate was 
the company expects to maintain tax benefits from its puerto rico operations in financial outlook worldwide neupogen r sales for are expected to grow at a rate lower than the growth rate 
future neupogen r sales increases are dependent primarily upon further penetration of existing markets  the timing and nature of additional indications for which the product may be approved and the effects of competitive products 
neupogen r usage is expected to continue to be affected by cost containment pressures on health care providers worldwide 
in addition  international neupogen r sales will continue to be subject to changes in foreign currency exchange rates and increased competition 
epogen r sales for are expected to grow at a rate lower than the growth rate 
the company anticipates that increases in both the us dialysis patient population and dosing will continue to drive epogen r sales 
the company believes that as more dialysis patients hematocrits reach target levels  the contribution of dosing to sales increases will diminish 
patients receiving treatment for end stage renal disease are covered primarily under medical programs provided by the federal government 
therefore  epogen r sales may also be affected by future changes in reimbursement rates or the basis for reimbursement by the federal government 
the company anticipates that total product sales and earnings will grow at double digit rates in  but these growth rates are expected to be lower than growth rates 
estimates of future product sales and earnings  however  are necessarily speculative in nature and are difficult to predict with accuracy 
except for the historical information contained herein  the matters discussed in this annual report on form k are by their nature forward looking 
for the reasons stated in this annual report or in the company s other securities and exchange commission filings  or for various unanticipated reasons  actual results may differ materially 
legal matters the company is engaged in arbitration proceedings with one of its licensees and various legal proceedings relating to synergen 
for a complete discussion of these matters see note to the consolidated financial statements 
page 
